Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose deutetrabenazine for tics in Tourette syndrome (pediatric)
2017-002976-24Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deutetrabenazine in Tourette syndrome (TS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in YGTSS Total Tic Score at week 8 (high-dose vs placebo). Started Apr 2018; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2017-002976-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002976-24.